Skip to main content

Goal Attainment and Physical Activity in People With Hemophilia A

Terminated · NCT06530030

Conditions: Hemophilia A

At a glance

Research payments reported, 2025
$123,871
U.S. investigators named
9
Sites paid
10
Planned or actual enrollment
3

About the trial

Sponsor
Sanofi
Tested
efanesoctocog alfa (drug)
Dates
Started 2024-11-26; completion 2025-09-18
Results posted
Not yet

This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan. This study aims to enroll 35 patients.

From ClinicalTrials.gov, last updated 2026-01-20. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $123,871 in research payments for this study in 2025 (31 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Administrators of the Tulane Educational Fund $23,469
  • Ut Health Gateway $19,833
  • Msu Center for Bleeding and Clotting Disorders $13,500
  • Vanderbilt University Medical Center, TN $13,058
  • Bleeding and Clotting Disorders Institute $11,664
  • Center for Comprehensive Care and Diagnosis of Inherited Blood Disorder $11,500
  • East Carolina University Health Hemophilia Treatment Center $11,500
  • Innovative Hematology Inc $11,500
  • Bleeding and Clotting Disorders Ins $4,947
  • Childrens Hospitals and Clinics Minnesota $2,900

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.